Different doses of amodiaquine and chloroquine for treatment of uncomplicated malaria in children in Guinea-Bissau: implications for future treatment recommendations

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 101, Issue 3, 2007, Pages 231-238

  Kofoed, Poul Erik ^a,b,c   Ursing, Johan ^c   Poulsen, Anja ^b   Rodrigues, Amabelia ^b   Bergquist, Yngve ^d   Aaby, Peter ^a,e   Rombo, Lars ^a,c,f,g  

^a Projecto de Saúde de Bandim ^*  (Guinea-Bissau)

^b KOLDING HOSPITAL   (Denmark)

^c KAROLINSKA INSTITUTE   (Sweden)

^d DALARNA UNIVERSITY   (Sweden)

^e DEPARTMENT OF EPIDEMIOLOGY RESEARCH   (Denmark)

^f Lab Nac da Saúde Pub   (Guinea-Bissau)

^g Division of Infectious Diseases Thoracic Medicine and Dermatology   (Sweden)

Author keywords

Amodiaquine; Chloroquine; Drug therapy; Malaria; Plasmodium falciparum; West Africa

Indexed keywords

AMODIAQUINE; CHLOROQUINE; QUINIMAX;

ADOLESCENT; ARTICLE; CHILD; CHILD CARE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVULSION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG RESPONSE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FEMALE; GUINEA-BISSAU; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; PRURITUS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VOMITING;

ADOLESCENT; AMODIAQUINE; ANTIMALARIALS; CHILD; CHILD, PRESCHOOL; CHLOROQUINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; MALARIA, FALCIPARUM; MALE; TREATMENT OUTCOME;

PLASMODIUM FALCIPARUM;

EID: 33846016251     PISSN: 00359203     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trstmh.2006.05.008     Document Type: Article

References (34)

1. Abacassamo F., Enosse S., Aponte J.J., Gomez-Olive F.X., Quinto L., Mabunda S., Barreto A., Magnussen P., Ronn A.M., Thompson R., and Alonso P.L. Efficacy of chloroquine, amodiaquine, sulphadoxine-pyrimethamine and combination therapy with artesunate in Mozambican children with non-complicated malaria. Trop. Med. Int. Health 9 (2004) 200-208
2. Adjuik M., Agnamey P., Babiker A., Borrmann S., Brasseur P., Cisse M., Cobelens F., Diallo S., Faucher J.F., Garner P., Gikunda S., Kremsner P.G., Krishna S., Lell B., Loolpapit M., Matsiegui P.B., Missinou M.A., Mwanza J., Ntoumi F., Olliaro P., Osimbo P., Rezbach P., Some E., and Taylor W.R. Amodiaquine-artesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children: a randomised, multicentre trial. Lancet 359 (2002) 1365-1372
3. Adjuik M., Babiker A., Garner P., Olliaro P., Taylor W., and White N. Artesunate combinations for treatment of malaria: meta-analysis. Lancet 363 (2004) 9-17
4. Barennes H., Nagot N., Valea I., Koussoube-Balima T., Ouedraogo A., Sanou T., and Ye S. A randomized trial of amodiaquine and artesunate alone and in combination for the treatment of uncomplicated falciparum malaria in children from Burkina Faso. Trop. Med. Int. Health 9 (2004) 438-444
5. Basco L.K., Same-Ekobo A., Ngane V.F., Ndounga M., Metoh T., Ringwald P., and Soula G. Therapeutic efficacy of sulfadoxine-pyrimethamine, amodiaquine and the sulfadoxine-pyrimethamine-amodiaquine combination against uncomplicated Plasmodium falciparum malaria in young children in Cameroon. Bull. World Health Organ. 80 (2002) 538-545
6. Bloland P.B., Ettling M., and Meek S. Combination therapy for malaria in Africa: hype or hope?. Bull. World Health Organ. 78 (2000) 1378-1388
7. Brasseur P., Guiguemde R., Diallo S., Guiyedi V., Kombila M., Ringwald P., and Olliaro P. Amodiaquine remains effective for treating uncomplicated malaria in west and central Africa. Trans. R. Soc. Trop. Med. Hyg. 93 (1999) 645-650
8. Checchi F., Roddy P., Kamara S., Williams A., Morineau G., Wurie A.R., Hora B., Lamotte N., Baerwaldt T., Heinzelmann A., Danks A., Pinoges L., Oloo A., Durand R., Ranford-Cartwright L., and Smet M. Evidence basis for antimalarial policy change in Sierra Leone: five in vivo efficacy studies of chloroquine, sulphadoxine-pyrimethamine and amodiaquine. Trop. Med. Int. Health 10 (2005) 146-153
9. Ginsburg H. Should chloroquine be laid to rest?. Acta Trop. 96 (2005) 16-23
10. Graupner J., Gobels K., Grobusch M.P., Lund A., Richter J., and Haussinger D. Efficacy of amodiaquine in uncomplicated falciparum malaria in Nigeria in an area with high-level resistance to chloroquine and sulphadoxine/pyrimethamine. Parasitol. Res. 96 (2005) 162-165
11. Hollis S., and Campbell F. What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ 319 (1999) 670-674
12. Kofoed P.E., Co F., Johansson P., Dias F., Cabral C., Hedegaard K., Aaby P., and Rombo L. Treatment of uncomplicated malaria in children in Guinea-Bissau with chloroquine, quinine, and sulfadoxine-pyrimethamine. Trans. R. Soc. Trop. Med. Hyg. 96 (2002) 304-309
13. Kofoed P.E., Lopez F., Johansson P., Sandstrom A., Hedegaard K., Aaby P., and Rombo L. Treatment of children with Plasmodium falciparum malaria with chloroquine in Guinea-Bissau. Am. J. Trop. Med. Hyg. 67 (2002) 28-31
14. Kofoed P.E., Poulsen A., Co F., Hedegaard K., Aaby P., and Rombo L. No benefits from combining chloroquine with artesunate for three days for treatment of Plasmodium falciparum in Guinea-Bissau. Trans. R. Soc. Trop. Med. Hyg. 97 (2003) 429-433
15. Kofoed P.E., Alfrangis M., Poulsen A., Rodrigues A., Gjedde S.B., Ronn A., and Rombo L. Genetic markers of resistance to pyrimethamine and sulfonamides in Plasmodium falciparum parasites compared with the resistance patterns in isolates of Escherichia coli from the same children in Guinea-Bissau. Trop. Med. Int. Health 9 (2004) 171-177
16. Kublin J.G., Cortese J.F., Njunju E.M., Mukadam R.A., Wirima J.J., Kazembe P.N., Djimde A.A., Kouriba B., Taylor T.E., and Plowe C.V. Reemergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi. J. Infect. Dis. 187 (2003) 1870-1875
17. Lindegardh N., Forslund M., Green M.D., Kaneko A., and Bergqvist Y. Automated solid-phase extraction for determination of amodiaquine, chloroquine and metabolites in capillary blood on sampling paper by liquid chromatography. Chromatographia 55 (2002) 5-12
18. Oduro A.R., Anyorigiya T., Hodgson A., Ansah P., Anto F., Ansah N.A., Atuguba F., Mumuni G., and Amankwa J. A randomized comparative study of chloroquine, amodiaquine and sulphadoxine-pyrimethamine for the treatment of uncomplicated malaria in Ghana. Trop. Med. Int. Health 10 (2005) 279-284
19. Olliaro, P., Mussano, P., 2000. Amodiaquine for treating malaria. Cochrane Database Syst. Rev. CD000016.
20. Olliaro P.L., and Taylor W.R. Developing artemisinin based drug combinations for the treatment of drug resistant falciparum malaria: a review. J. Postgrad. Med. 50 (2004) 40-44
21. Olliaro P., Nevill C., LeBras J., Ringwald P., Mussano P., Garner P., and Brasseur P. Systematic review of amodiaquine treatment in uncomplicated malaria. Lancet 348 (1996) 1196-1201
22. Sangho H., Diawara A., Diallo M., Sow S., Sango H.A., Sacko M., and Doumbo O. Assessment of chloroquine resistance two years after stopping chemoprophylaxis in 0 to 9-year-old children living in a malaria-endemic village of Mali. Med. Trop. (Mars.) 64 (2004) 506-510 [in French]
23. Schwenke A., Brandts C., Philipps J., Winkler S., Wernsdorfer W.H., and Kremsner P.G. Declining chloroquine resistance of Plasmodium falciparum in Lambarene, Gabon from 1992 to 1998. Wien. Klin. Wochenschr. 113 (2001) 63-64
24. Sexton J.D., Deloron P., Bugilimfura L., Ntilivamunda A., and Neill M. Parasitologic and clinical efficacy of 25 and 50 mg/kg of chloroquine for treatment of Plasmodium falciparum malaria in Rwandan children. Am. J. Trop. Med. Hyg. 38 (1988) 237-243
25. Simpson J.A., Watkins E.R., Price R.N., Aarons L., Kyle D.E., and White N.J. Mefloquine pharmacokinetic-pharmacodynamic models: implications for dosing and resistance. Antimicrob. Agents Chemother. 44 (2000) 3414-3424
26. Slater M., Kiggundu M., Dokomajilar C., Kamya M.R., Bakyaita N., Talisuna A., Rosenthal P.J., and Dorsey G. Distinguishing recrudescences from new infections in antimalarial clinical trials: major impact of interpretation of genotyping results on estimates of drug efficacy. Am. J. Trop. Med. Hyg. 73 (2005) 256-262
27. Snounou G., Zhu X., Siripoon N., Jarra W., Thaithong S., Brown K.N., and Viriyakosol S. Biased distribution of msp1 and msp2 allelic variants in Plasmodium falciparum populations in Thailand. Trans. R. Soc. Trop. Med. Hyg. 93 (1999) 369-374
28. Sowunmi A., Ayede A.I., Falade A.G., Ndikum V.N., Sowunmi C.O., Adedeji A.A., Falade C.O., Happi T.C., and Oduola A.M. Randomized comparison of chloroquine and amodiaquine in the treatment of acute, uncomplicated, Plasmodium falciparum malaria in children. Ann. Trop. Med. Parasitol. 95 (2001) 549-558
29. Staedke S.G., Kamya M.R., Dorsey G., Gasasira A., Ndeezi G., Charlebois E.D., and Rosenthal P.J. Amodiaquine, sulfadoxine/pyrimethamine, and combination therapy for treatment of uncomplicated falciparum malaria in Kampala, Uganda: a randomised trial. Lancet 358 (2001) 368-374
30. Taylor W.R., and White N.J. Antimalarial drug toxicity: a review. Drug Saf. 27 (2004) 25-61
31. Watkins W.M., Sibley C.H., and Hastings I.M. The search for effective and sustainable treatments for Plasmodium falciparum malaria in Africa: a model of the selection of resistance by antifolate drugs and their combinations. Am. J. Trop. Med. Hyg. 72 (2005) 163-173
32. White N.J. Antimalarial drug resistance. J. Clin. Invest. 113 (2004) 1084-1092
33. WHO, 2005. Susceptibility of Plasmodium falciparum to antimalarial drugs. Report on global monitoring 1996-2004. World Health Organization, Geneva.
34. Yeka A., Banek K., Bakyaita N., Staedke S.G., Kamya M.R., Talisuna A., Kironde F., Nsobya S.L., Kilian A., Slater M., Reingold A., Rosenthal P.J., Wabwire-Mangen F., and Dorsey G. Artemisinin versus nonartemisinin combination therapy for uncomplicated malaria: randomized clinical trials from four sites in Uganda. PLoS Med. 2 (2005) e190